Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electroacupuncture and Zilongjin in resectable NSCLC
NCT07034326Phase 3Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (3 arms). Primary endpoint: Disease Free Survival at 2 years. Started Jan 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07034326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034326.